Volume 118, Issue 3 , Pages 734-741, September 2006
Immunization with a low-dose replicon DNA vaccine encoding Phl p 5 effectively prevents allergic sensitization
Background
Replicase-based DNA vaccines stimulate TH1-biased immune responses at ultralow doses and induce self-removal of transfected cells through apoptosis. Both aspects are important requirements for efficient and safe DNA-based immunotherapy of type I allergies.
Objective
A Sindbis virus replicon-based DNA vaccine encoding the major timothy grass pollen allergen Phl p 5 was evaluated for its antiallergic potential compared with a conventional DNA vaccine in a BALB/c mouse model of allergy.
Methods
Mice were intradermally prevaccinated with plasmid DNA, followed by sensitization and intranasal allergen provocation with recombinant Phl p 5. In vitro proliferation and cytokine secretion was measured in splenocyte cultures. Distribution of IgG1, IgG2a, and IgE antibody subclasses was determined by means of ELISA. IgE-mediated degranulation was measured with the basophil release assay. Bronchoalveolar lavage fluid was analyzed for eosinophils, IL-4, IL-5, IL-13, and IFN-γ. Mucus production, inflammatory infiltrates, and epithelial damage were determined in lung sections.
Results
Both vaccines induced TH1-biased immune responses, resulting in suppression of functional IgE, reduction of eosinophilia in bronchoalveolar lavage fluid, and alleviation of lung pathology. However, immunization with the replicon DNA vaccine elicited these effects at a 100-fold lower dose compared with the conventional DNA vaccine.
Conclusions
The increased immunogenicity of replicon-based DNA vaccines allows for application of extremely low doses, thereby eliminating the concerns associated with conventional DNA vaccines, which have to be administered at milligram amounts to induce immune reactions in human subjects.
Clinical implications
Their high safety profile makes replicon-based DNA vaccines promising candidates for treatment of type I allergies in the clinic.
Key words: Type I allergy, DNA vaccine, genetic immunization, replicase, alphavirus, Phl p 5, IgE, bronchoalveolar lavage, eosinophils, lung pathology
Abbreviations used: BAL, Bronchoalveolar lavage, H&E, Hematoxylin and eosin, PAS, Periodic acid–Schiff, pCMV, DNA expression vector without insert, pCMV-P5, DNA expression vector encoding Phl p 5, pSin, Sindbis replicon-based DNA expression vector without insert, pSin-P5, Sindbis replicon-based DNA expression vector encoding Phl p 5, TLR, Toll-like receptor
Supported by the Austrian Science Foundation, project no. S8811, S8813, and T133-B08; the CeMM project of the Austrian Academy of Sciences; and the Ludwig Boltzmann Institute for Experimental Surgery.Disclosure of potential conflict of interest: The authors have declared that they have no conflict of interest.
PII: S0091-6749(06)00943-2
doi:10.1016/j.jaci.2006.04.048
© 2006 American Academy of Allergy, Asthma and Immunology. Published by Elsevier Inc. All rights reserved.
Volume 118, Issue 3 , Pages 734-741, September 2006
